Q-omics provides the consensus-scored KLHL22 profile across patient tissues and cancer cell-line models. KLHL22 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, KLHL22 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, KLHL22 RNA expression shows 19,857 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCEC, HNSC, and ACC as cancer lineages where KLHL22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHL22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHL22 survival associations across molecular data types. KLHL22 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHL22 RNA expression–survival associations across cancer types. High KLHL22 expression shows unfavorable associations in UVM, ACC and LIHC, but favorable associations in UCEC, PAAD and KIRP. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for KLHL22 RNA expression.
This table summarizes KLHL22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KLHL22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHL22 shows lower tumor expression in THCA and KIRP and higher tumor expression in HNSC, LIHC, CHOL and LUSC. The HNSC box plot shows higher KLHL22 RNA expression in tumor versus normal tissue (log2 FC = +0.846, t-test p < 0.001).
This table shows molecular features associated with KLHL22 in patient tissues and cancer cell lines. In patient samples, KLHL22 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHL22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
